AR052191A1 - Metodo de tratamiento - Google Patents

Metodo de tratamiento

Info

Publication number
AR052191A1
AR052191A1 ARP060100058A ARP060100058A AR052191A1 AR 052191 A1 AR052191 A1 AR 052191A1 AR P060100058 A ARP060100058 A AR P060100058A AR P060100058 A ARP060100058 A AR P060100058A AR 052191 A1 AR052191 A1 AR 052191A1
Authority
AR
Argentina
Prior art keywords
disorders
related disorders
substance
pharmaceutically acceptable
limited
Prior art date
Application number
ARP060100058A
Other languages
English (en)
Spanish (es)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR052191A1 publication Critical patent/AR052191A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
ARP060100058A 2005-01-07 2006-01-06 Metodo de tratamiento AR052191A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US64226205P 2005-01-07 2005-01-07
US73786405P 2005-11-18 2005-11-18
US73786505P 2005-11-18 2005-11-18
US73788705P 2005-11-18 2005-11-18

Publications (1)

Publication Number Publication Date
AR052191A1 true AR052191A1 (es) 2007-03-07

Family

ID=36647771

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060100058A AR052191A1 (es) 2005-01-07 2006-01-06 Metodo de tratamiento

Country Status (6)

Country Link
EP (1) EP1838325A1 (fr)
JP (1) JP2008526839A (fr)
AR (1) AR052191A1 (fr)
TW (1) TW200640466A (fr)
UY (1) UY29326A1 (fr)
WO (1) WO2006073360A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007062339A2 (fr) * 2005-11-18 2007-05-31 Astrazeneca Ab Formulations liquides
CN102131791B (zh) 2008-06-20 2014-12-24 阿斯利康(瑞典)有限公司 二苯并硫杂氮杂*衍生物及其用途
WO2010085976A1 (fr) * 2009-01-30 2010-08-05 F.I.S. Fabbrica Italiana Sintetici S.P.A. Procédé pour la synthèse de quétiapine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US7071133B2 (en) * 1993-11-16 2006-07-04 Ppg Industries Ohio, Inc. Colored glass compositions and-automotive vision panels with-reduced transmitted-color shift
US5602124A (en) * 1994-12-12 1997-02-11 Allelix Biopharmaceuticals, Inc. 5-HT2 receptor ligands
SE0003126D0 (sv) * 2000-09-05 2000-09-05 Astrazeneca Ab Method of treatment
US7304047B2 (en) * 2001-02-06 2007-12-04 Astrazeneca Ab Method of treating substance abuse with quetiapine
US20060189599A1 (en) * 2002-10-18 2006-08-24 Green Alan I Treating alcohol and or substance abuse by antagonizing alpha 2 adrenergic receptors with weak dopamine blocking
KR20060082037A (ko) * 2003-07-02 2006-07-14 아스트라제네카 아베 퀘티아핀의 대사산물
CA2547652A1 (fr) * 2003-12-04 2005-06-16 The Research Foundation Of The City University Of New York Effets de la clozapine et de la cocaine sur la liberation de dopamine et de serotonine dans le noyau accumbens pendant un comportement psychostimulant et sevrage
PT1696931E (pt) * 2003-12-22 2009-06-12 Acadia Pharm Inc Análogos diaril[a,d]ciclo-hepteno substituídos com amino utilizados como agonistas muscarínicos e métodos de tratamento de perturbações neuropsiquiátricas
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic

Also Published As

Publication number Publication date
UY29326A1 (es) 2006-08-31
TW200640466A (en) 2006-12-01
JP2008526839A (ja) 2008-07-24
EP1838325A1 (fr) 2007-10-03
WO2006073360A1 (fr) 2006-07-13

Similar Documents

Publication Publication Date Title
Bhutada et al. Reversal by quercetin of corticotrophin releasing factor induced anxiety-and depression-like effect in mice
Serretti et al. New antipsychotics and schizophrenia: a review on efficacy and side effects
BR0210711A (pt) Uso de um composto, composição farmacêutica, composto, e, processo para a preparação de um composto
BRPI0607017B8 (pt) composição farmacêutica compreendendo memantina e donezepil, e seu uso para o tratamento de condições relacionadas ao snc
BRPI0519181A2 (pt) composto ou um sal farmaceuticamente aceitÁvel do mesmo, processo para preparar o mesmo, composiÇço farmacÊutica, uso de um composto ou um sal farmaceuticamente aceitÁvel do mesmo, e, mÉtodos para produzir um efeito inibitàrio de b-raf em um animal de sangue quente, para produzir um efeito anti-cÂncer em um animal de sangue quente e para tratar uma doenÇa em um animal de sangue quente
EP1765362A4 (fr) Compositions et méthodes pour le traitement de maladies néovasculaires
WO2007002516A3 (fr) Formes de dosage ameliorees pour le traitement de troubles moteurs
EP1478371A4 (fr) Methodes et produits permettant d'ameliorer des reponses immunitaires a l'aide de compose d'imidazoquinoline
BR0317358A (pt) Composto de pirrolopiridazina, processo para sua preparação, composição farmacêutica contendo o mesmo, método de prevenção ou tratamento de doenças contendo o mesmo e seu uso
BRPI0417959A (pt) anticorpo ou fragmento funcional deste, composição farmcêutica, método para tratamento ou profilaxia de acidente vascular cerebral e outras doenças/distúrbios neurológicos em um ser humano, uso de um anticorpo anti-nogo, e, métodos para inibir a neurodegeneração e/ou promover a recuperação funcional em um paciente humano, para promover o crescimento axonal, para produzir um anticorpo anti-nogo e para produzir uma composição farmacêutica intravenosamente administrável
BRPI0411906A (pt) compostos, processo para a sua preparação, composições farmacêuticas que compreendem os mesmos, método para tratar ou prevenir uma enfermidade mediada pela ativação da enzima de sintase de glicogênio, e utilização dos compostos
BRPI0414428A (pt) composições farmacêuticas
UY30659A1 (es) Grupo de compuestos de benzoilamino heterociclico, composiciones farmacéuticas, porcesos para su preparacion y aplicaciones.
AR062068A1 (es) Sal tartrato de(7)s-7-[(5-fluoro-2-metil-bencil)oxi]-2-[(2r)-2-metilpiperazin-il]-6,7-dihidro-5h-ciclopenta[b]piridina, composiciones farmaceuticas que la contienen, y usos en trastornos asociados fundamentalmente al scn
Niu et al. The effects of hispidulin on bupivacaine-induced neurotoxicity: role of AMPK signaling pathway
BR0312232A (pt) Inibidores de caspases e seus usos
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
WO2006053049A3 (fr) Composition phytotherapeutique phy906 et son utilisation en chimiotherapie
Serata et al. Are 5‐HT3 antagonists effective in obsessive–compulsive disorder? A systematic review of literature
Devi Milk thistle (Silybum marianum)
Takeuchi et al. Rakicidin A effectively induces apoptosis in hypoxia adapted Bcr‐Abl positive leukemic cells
FI20095600A7 (fi) Koostumus ihosairauksien hoitoa varten
Abbas et al. Natural immunomodulators treat the cytokine storm in SARS-CoV-2
Sebastian et al. Pentoxifylline inhibits replication of Japanese encephalitis virus: a comparative study with ribavirin
WO2005094554A3 (fr) Agents, methodes et traitements therapeutiques

Legal Events

Date Code Title Description
FA Abandonment or withdrawal